XGEN Venture
—
SectorsHealthcare2
Regions—
Last activity
Activity, last 12 months
| Month | Deals |
|---|---|
| November 2025 | 0 |
| December 2025 | 1 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 0 |
| August 2026 | 0 |
| September 2026 | 0 |
| October 2026 | 1 |
Deal history
Dialybrid raises EUR 15m to advance Silkothane graft
Italian vascular-access medtech Dialybrid has closed a EUR 15 million Series A led by XGEN Venture with CDP Venture Capital participation, funding a first-in-human trial of its Silkothane arteriovenous graft and broader preclinical work.
EpilepsyGTx lands EUR 31.75m to advance epilepsy gene therapy
UK gene therapy start-up EpilepsyGTx has raised EUR 31.75 million in Series A funding from XGEN Venture, the British Business Bank and a global biopharma to take EPY201 into Phase 1/2a trials for focal refractory epilepsy.